Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 742 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Migraine Headache Clear all
Completed Phase 2Phase 3 Interventional Results available

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192
View directory record Official record
Conditions
Refractory Migraine
Interventions
Botox, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 9, 2026, 9:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

NCT01981499
View directory record Official record
Conditions
Migraine
Interventions
PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

NCT00632385
View directory record Official record
Conditions
Migraine
Interventions
Eletriptan
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
16
States / cities
Irvine, California • Newport Beach, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

NCT00440518
View directory record Official record
Conditions
Migraine
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura

NCT00449540
View directory record Official record
Conditions
Migraine With Aura
Interventions
Active Transcranial Magnetic Stimulation (TMS) Device, Sham TMS Device
Device
Lead sponsor
Neuralieve
Industry
Eligibility
18 Years to 65 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Temporal, Environmental, and Genetic Factors Regulating Exercise and Migraine

NCT04553445
View directory record Official record
Conditions
Migraine Disorders
Interventions
Chronotype, Green exercise
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Tinnitus With Migraine Medications

NCT04404439
View directory record Official record
Conditions
Tinnitus, Subjective, Tinnitus
Interventions
Nortriptyline + Topiramate, Verapamil + Paroxetine, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 9, 2026, 9:38 AM EDT
Completed No phase listed Observational

A Survey Study to Assess the Accessibility of the Nerivio Device At School

NCT06180577
View directory record Official record
Conditions
Migraine in Children
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
Up to 18 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Staccato Prochlorperazine in Migraine (Out Patient)

NCT00422812
View directory record Official record
Conditions
Migraine Headache, Aura
Interventions
Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 9, 2026, 9:38 AM EDT
Terminated Not applicable Interventional Results available

A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache

NCT02991430
View directory record Official record
Conditions
Intervention
Interventions
active neuromodulation for episodic migraine headache, placebo neuromodulation for episodic migraine headache
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • West Palm Beach, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 9, 2026, 9:38 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Mechanistic Studies of Psilocybin in Headache Disorders

NCT06464367
View directory record Official record
Conditions
Migraine
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

NCT03055767
View directory record Official record
Conditions
Migraine Disorders, Headache, Migraine, Pediatrics
Interventions
OnabotulinumtoxinA, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
8 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 9, 2026, 9:38 AM EDT
Completed No phase listed Observational Results available

Research Study to Determine Sensitivity to Gentle Touch and Pressure During an Active Migraine Attack.

NCT00329771
View directory record Official record
Conditions
Migraine
Interventions
No intervention: We are testing for the presence of allodynia
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

NCT04828707
View directory record Official record
Conditions
Migraine
Interventions
Nerivio active device, Nerivio sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Carlsbad, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack

NCT00530517
View directory record Official record
Conditions
Migraine Headache
Interventions
Intraject Sumatriptan
Device
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Not applicable Interventional

A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache

NCT00287781
View directory record Official record
Conditions
Migraine Headache
Interventions
Lidocaine
Drug
Lead sponsor
Kern Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

NCT01813591
View directory record Official record
Conditions
Chronic Migraine
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Not applicable Interventional

RELAXaHEAD for Headache Patients (Phase I)

NCT03183791
View directory record Official record
Conditions
Headache, Migraine, Multiple Sclerosis
Interventions
RELAXaHEAD app, Monitored Usual Care (MUC)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 3 Interventional

A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack

NCT00510419
View directory record Official record
Conditions
Migraine
Interventions
"Investigational"Auto-injector (sumatriptan succinate)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
San Francisco, California • Stamford, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 9, 2026, 9:38 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of Sumatriptan With Naprosyn in Migraine With Aura

NCT00893594
View directory record Official record
Conditions
Migraine With Aura
Interventions
sumatriptan with naprosyn, placebo
Drug
Lead sponsor
Dent Neurologic Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

NCT00806546
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 9, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting

NCT00440232
View directory record Official record
Conditions
Migraine
Interventions
Frovatriptan, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 9, 2026, 9:38 AM EDT